Contact
searchSearch
HMP Global
Login

Melanoma

Melanoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Georgina Long, MD, PhD
Videos
Neoadjuvant Nivolumab Plus Relatlimab Produces Deep Responses in High-Risk Melanoma
06/19/2026
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses results from the phase 2 NEO-RENI-2 trial showing that neoadjuvant nivolumab plus relatlimab achieved a 60% pathologic complete response rate and 65% major pathologic response rate in patients with resectable...
Georgina Long, MD, PhD, discusses results from the phase 2 NEO-RENI-2 trial showing that neoadjuvant nivolumab plus relatlimab achieved a 60% pathologic complete response rate and 65% major pathologic response rate in patients with resectable...
Georgina Long, MD, PhD,...
06/19/2026
Oncology
Katharina Kaehler, MD
Videos
Novel Neoadjuvant Approach Expands Treatment Options for Patients With Melanoma
06/18/2026
Katharina Kaehler, MD
Katharina Kaehler, MD, discusses updated results from the phase 3 PIVOTAL trial showing that neoadjuvant intralesional immunotherapy significantly improved relapse-free, distant metastasis-free, and event-free survival compared with upfront...
Katharina Kaehler, MD, discusses updated results from the phase 3 PIVOTAL trial showing that neoadjuvant intralesional immunotherapy significantly improved relapse-free, distant metastasis-free, and event-free survival compared with upfront...
Katharina Kaehler, MD, discusses...
06/18/2026
Oncology
Marlana Orloff, MD
Videos
Darovasertib Plus Crizotinib Combination Demonstrates Meaningful Clinical Benefit in Metastatic Uveal Melanoma
06/15/2026
Marlana Orloff, MD
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses...
06/15/2026
Oncology
Jessica Hassel, MD
Videos
Immune Modulatory Vaccine Plus Pembrolizumab for First-Line Treatment of Patients With Advanced Melanoma
10/30/2025
Jessica Hassel, MD
Jessica Hassel, MD, shares results from a phase 3 trial evaluating the IO102-IO103 cancer vaccine in combination with pembrolizumab in the first-line setting for patients with advanced melanoma in the first line.
Jessica Hassel, MD, shares results from a phase 3 trial evaluating the IO102-IO103 cancer vaccine in combination with pembrolizumab in the first-line setting for patients with advanced melanoma in the first line.
Jessica Hassel, MD, shares...
10/30/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology

Recent News

News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology
News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use